

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This announcement is made by Ascletis Pharma Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board of directors (the “**Board**”) of the Company announces that Ascletis BioScience Co., Ltd. (“**Ascletis BioScience**”, a wholly-owned subsidiary of the Company incorporated in the People’s Republic of China) and Shanghai Roche Pharmaceuticals Ltd. (“**Roche Pharma China**”) completed the signing of an addendum agreement on September 16, 2022, pursuant to which the promotion services for Pegasys® (a pegylated interferon for treatment of Hepatitis B and C) provided by Ascletis BioScience to Roche Pharma China will be terminated with effect from December 31, 2022. The promotion service for Pegasys® was started from December 2018 pursuant to the partnership agreement between Ascletis BioScience and Roche Pharma China dated November 20, 2018 (the “**Partnership Agreement**”). Under the Partnership Agreement, Ascletis BioScience was granted an exclusive marketing promotion right for promotion services of Pegasys® in Mainland China and in turn entitled to receive a certain percentage of the sales revenue as consideration. After a long-term and successful cooperation and based on the strategic adjustment made by Roche Pharma China with regard to Mainland China market, Ascletis BioScience and Roche Pharma China have agreed that the two parties will not continue the partnership for promotion of Pegasys® in Mainland China market with effect from December 31, 2022. Roche Pharma China will neither seek other partner, nor by itself, to conduct promotion of Pegasys® in Mainland China.

Taking into account the Company’s continuing effort in improving its operational efficiency, the Board is of the view that the termination of promotion service for Pegasys® will not cause any material adverse impact on the business, operation or financial condition of the Group. As of the date of this announcement, the Company has established a robust pipeline including three approved products in China and multiple drug candidates at Phase II or Phase III clinical development.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
September 16, 2022

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.